First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan

On September 27, 2017 Takara Bio Inc. (Takara Bio), reported that the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on September　26, 2017 (Press release, Takara Bio, SEP 27, 2017, View Source [SID1234520647]).

This clinical trial will be conducted in patients with unresectable advanced pancreatic cancer to evaluate safety of HF10 in combination with existing chemotherapeutic drug.

In this clinical trial, the HF10 manufactured at Center for Gene and Cell Therapy, Takara Bio’s facility, will be used.
Regarding domestic development and sales of oncolytic virus HF10, Takara Bio has an exclusive licensing agreement with Otsuka Pharmaceutical Co., Ltd., and both companies will consult with each other and aim for the early approval of HF10 in Japan.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!